Selamat Budijitno, Satrio Putra Prawiro, Eriawan Agung Nugroho, Luqman Alwi, Putu Anda Tusta Adiputra
Background: Breast cancer has the highest incidence of cancer in women. The first-line chemotherapy, Adriamycin-cyclophosphamide (AC) has good results, but its efficacy is not optimal. The fruit lectin substance Abelmoschus esculentus has an anti-cancer effect, so it is widely used as a chemotherapy supplement. The aim of the study is to prove Abelmoschus esculentus extract can increase the apoptotic index against chemotherapy Method: In vivo laboratory trial study, we are using Sprague Dawley female rats aged 28 days with mammary adenocarcinoma induced by DMBA. There are 4 groups, namely; control (K): placebo, treatment1 (P1): AC chemotherapy (Adriamycin 1.5 mg and cyclophosphamide 15 mg), treatment2 (P2): Abelmoschus esculentus extract 150 mg/kgBB/day, and treatment3 (P3): a combination of AC and Abelmoschus esculentus extract. Results: The P3 group had the highest levels of Endonuclease_G (EndoG) and apoptosis at (38.66 ± 0.73) and (21.03 ± 0.69), respectively. Combination of Abelmoschus esculentus extract with chemotherapeutic agents can improve the anticancer outcome by significantly increasing EndoG expression and apoptosis index (p<0.05) in comparison to other groups. Conclusion: Extract from Abelmoschus esculentus fruit shows high apoptotic index and EndoG expression which means that this extract can increase the apoptotic response to in vivo in-cyclophosphamide adriamis chemotherapy. © 2023, Sanglah General Hospital. All rights reserved.
Surgical Department, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia; Surgical Department, Faculty of Medicine, Universitas Negeri Semarang, Indonesia; Surgical Department, Faculty of Medicine, Universitas Udayana Denpasar, Indonesia
